EUVIMEDEUVIMED entdecken
Fallbericht

Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib

Sun Yao, Liu Na, Hu Liangding

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05832-7 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2024. Verfasst von Sun Yao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Hematology, the Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Eosinophilia, Fusion Proteins, bcr-abl, Imatinib Mesylate, Myeloproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here, we present a rare case of myeloproliferative neoplasms (MPN) with eosinophilia harboring both BCR::ABL1 and PDGFRB rearrangements, posing a classification dilemma. The patient exhibited clinical and laboratory features suggestive of chronic myeloid leukemia (CML) and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK), highlighting the diagnostic challenges associated with overlapping phenotypes. Despite the complexity, imatinib treatment swiftly achieved deep molecular remission, underscoring the therapeutic efficacy of tyrosine kinase inhibitors in such scenarios. Furthermore, the rapid attainment of deep remission by this patient in response to imatinib closely resembles that observed in MLN-TK patients with PDGFRB rearrangements. Further research is warranted to elucidate the underlying mechanisms driving the coexistence of multiple oncogenic rearrangements in MPNs and to optimize therapeutic strategies for these complex cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EosinophiliaFusion Proteins, bcr-ablImatinib MesylateMyeloproliferative DisordersReceptor, Platelet-Derived Growth Factor betaHumansMaleGene RearrangementProtein Kinase InhibitorsYoung Adult

Stichwörter der Autor:innen

BCR:ABL1CMLMLN-TKMPNPDGFRB

Substanzen

Fusion Proteins, bcr-ablImatinib MesylatePDGFRB protein, humanProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor beta

Autor:innen und Institutionen

  • Senior Department of Hematology, the Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
  • Senior Department of Hematology, the Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China. huliangding@sohu.com.

Förderung

  • the National Natural Science Foundation of China

Zitieren

APA

Yao, S., Na, L., & Liangding, H. (2024). Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib. Annals of Hematology. https://doi.org/10.1007/s00277-024-05832-7

Vancouver

Yao S, Na L, Liangding H. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib. Annals of Hematology. 2024. doi:10.1007/s00277-024-05832-7

BibTeX
@article{Yao2024,
  author = {Yao, Sun and Na, Liu and Liangding, Hu},
  title = {Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05832-7}
}
Kostenlos starten →